ClouDr Group (FRA:H3L) Short-Term Debt: €31.4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H3L ClouDr Group Ltd FRA:H3L
48 GF Score
Price €0.05
GF Value €0.08
! 9 Warning Signs
View Full Analysis

What is ClouDr Group Short-Term Debt?

ClouDr Group FRA:H3L 48 Short-Term Debt is €31.4 Mil as of Dec. 2025. GuruFocus rates FRA:H3L with a GF Score™ of 48/100 and a GF Value™ of €0.08. The stock has 9 warning signs investors should review.

ClouDr Group's Short-Term Debt for the quarter that ended in Dec. 2025 was €31.4 Mil.

ClouDr Group's quarterly Short-Term Debt declined from Dec. 2024 (€43.4 Mil) to Jun. 2025 (€35.6 Mil) and declined from Jun. 2025 (€35.6 Mil) to Dec. 2025 (€31.4 Mil).

ClouDr Group's annual Short-Term Debt increased from Dec. 2023 (€28.3 Mil) to Dec. 2024 (€43.4 Mil) but then declined from Dec. 2024 (€43.4 Mil) to Dec. 2025 (€31.4 Mil).

ClouDr Group Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

ClouDr Group Short-Term Debt Related Terms

ClouDr Group Short-Term Debt Historical Data

* Premium members only.

The historical data trend for ClouDr Group's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClouDr Group Short-Term Debt Chart

ClouDr Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 1,253.60 26.07 28.26 43.41 31.40

ClouDr Group Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.26 43.85 43.41 35.63 31.40
FRA:H3L
48GF Score
ClouDr Group Ltd FRA:H3L
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €31.4 Mil mean?
ClouDr Group (FRA:H3L) has a Short-Term Debt of €31.4 Mil as of Dec. 2025.
Is ClouDr Group's Short-Term Debt too high?
ClouDr Group's current Short-Term Debt is €31.4 Mil. Overall, ClouDr Group has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's Short-Term Debt compare to MCK and COR?
ClouDr Group's Short-Term Debt of €31.4 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Distribution company?
A good Short-Term Debt depends on the Medical Distribution industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. ClouDr Group's current Short-Term Debt is €31.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
ClouDr Group (FRA:H3L) has a current Short-Term Debt of €31.4 Mil. The stock's GF Value™ is €0.08, compared to a current price of €0.05 — trading 36.9% below its estimated fair value. The current Short-Term Debt is €31.4 Mil. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For ClouDr Group (FRA:H3L), the current Short-Term Debt is €31.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ClouDr Group (FRA:H3L) Overvalued in 2026?

Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued. The current stock price of €0.05 is trading 36.9% below its estimated GF Value™ of €0.08.

Key valuation signals for FRA:H3L:

  • Short-Term Debt: €31.4 Mil
  • GF Value™: €0.08 vs. price of €0.05 (36.9% below fair value)
  • GF Score™: 48/100 with 9 warning signs

No single metric tells the full story. See the FRA:H3L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ClouDr Group Business Description

Other Exchanges 09955:Hong Kong
Address No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score

Get the complete analysis for FRA:H3L

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price
€0.08
GF Value